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Abstract
Background: Addition of intrathecal magnesium sulfate to local anesthetics has been reported to potentiate spinal
anesthesia and prolong analgesia in parturients. The current study was to determine whether intrathecal magnesium
sulfate would reduce the dose of hyperbaric bupivacaine in spinal anesthesia with bupivacaine and sufentanil for
cesarean delivery.
Methods: Sixty healthy parturients undergoing scheduled cesarean delivery were randomly assigned to receive spinal
anesthesia with 0.5% hyperbaric bupivacaine and 5 μg sufentanil with either 0.9% sodium chloride (Control group) or
50% magnesium sulfate (50 mg) (Magnesium group). Effective anesthesia was defined as a bilateral T5 sensory block
level achieved within 10 min of intrathecal drug administration and no additional epidural anesthetic was required
during surgery. Characteristic of spinal anesthesia and the incidence of side effects were observed. The ED50 for both
groups was calculated using the Dixon and Massey formula.
Results: There was no significant difference in the ED50 of bupivacaine between the Magnesium group and the Control
group (4.9 mg vs 4.7 mg) (P = 0.53). The duration of spinal anesthesia (183 min vs 148 min, P < 0.001) was longer, the
consumption of fentanyl during the first 24 h postoperatively (343 μg vs 550 μg, P < 0.001) was lower in the Magnesium
group than that in the Control group.
Conclusions: Intrathecal magnesium sulfate (50 mg) did not reduce the dose requirement of intrathecal bupivacaine, but
can extend the duration of spinal anesthesia with no obvious additional side effects.
Trial registration: This study was registered with Chinese Clinical Trial Registry (ChiCTR) on 15 Jul. 2014 and was given a
trial ID number ChiCTR-TRC-14004954.
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Background
Spinal anesthesia is the most widely used technique for
cesarean delivery mainly due to its rapid onset and reliable
effect [1, 2]. The main limitations of spinal anesthesia are
the relatively short duration of anesthesia and analgesia,
and high incidence of hypotension. To minimize these limi-
tations, intrathecal adjuncts such as opioids, clonidine, neo-
stigmine and epinephrine have been reportedly used for
prolonging analgesia and reducing the dose of intrathecal
local anesthetic, and subsequently reducing the incidence
of spinal anesthesia-induced hypotension [3–5]. However,
intrathecal opioids such as fentanyl and sufentanil, which
are commonly used as adjuncts to intrathecal local
anesthetic, are associated with a number of undesirable
side-effects, including delayed respiratory depression, urin-
ary retention, and pruritus [6–8]. In addition, other ad-
juncts, such as clonidine, neostigmine and epinephrine, also
exhibit adverse effects such as sedation and so on [9, 10].
Magnesium ion is a natural calcium antagonist, which is
critical to numerous physiological activities. Animal studies
showed that intrathecal magnesium could produce an anal-
gesic effect and enhance opioid’s antinociceptive activity,
presumably due to magnesium’s possible block of the N-
methyl-D-aspartate (NMDA) receptor and regulate calcium
influx into cells in the central nervous system [11, 12]. Sev-
eral recent studies [13, 14] investigated the utility of magne-
sium as an adjunct to intrathecal local anesthetics for both
obstetrical and nonobstetrical surgery, aiming to overcome
the limitations of spinal anesthesia, which main findings are
that the addition of magnesium sulfate to intrathecal local
anesthetics with or without opioids could prolong the dur-
ation of analgesia, reduce postoperative analgesic require-
ments, and improve perioperative shivering without
significant side effects. No previous studies have assessed
whether the addition of intrathecal magnesium sulfate can
reduce the dose of intrathecal local anesthetic required for
spinal anesthesia for cesarean delivery. We therefore de-
signed the present prospective, randomized, double blinded
study to investigate the hypothesis that intrathecal magne-
sium sulfate (MgSO4) 50 mg would decrease the median ef-
fective dose (ED50, which means the dose that would be
necessary to provide effective anesthesia for 50% of the pa-
tients treated) of intrathecal hyperbaric bupivacaine in
spinal bupivacaine-sufentanil anesthesia for cesarean deliv-
ery using an up-down sequential allocation method.
Methods
Design
We conducted a prospective, double-blinded, up-down se-
quential allocation study to determine the ED50 of intra-
thecal hyperbaric bupivacaine combined with or without
MgSO4, in spinal bupivacaine-sufentanil anesthesia for
cesarean delivery in healthy parturients.
Subjects and setting
Sixty healthy (ASA PS I, II) parturients at term pregnancy,
undergoing elective cesarean section, were enrolled in the
current study, which was conducted from July 2014 to
August 2014. Subjects were enrolled after our hospital’s
(Women’s Hospital, School of Medicine, Zhejiang Univer-
sity) ethical review board approval (No: 20140069. Ap-
proval date: 2014 Jul 15) and written informed consent
have been obtained. Exclusion criteria were patients with
obesity (body mass index (BMI) > 35 kg/m2), gestational
age < 37 weeks, active labor, early labor, ruptured mem-
branes, history of previous cesarean deliveries, diabetes or
gestational diabetes, hypertension or pre-eclampsia, intra-
uterine growth restriction, placenta previa, significant
coexisting maternal disease, any contraindication to spinal
or epidural anesthesia such as local infection or bleeding
disorders. This study was registered in a Chinese Clinical
Trial Registry (ChiCTR) (registration number is ChiCTR-
TRC-14004954).
Study protocol
Patients were randomized into one of two groups, Control
group (n = 30) and Magnesium group (n = 30), based on a
computer-generated random number list (Microsoft,
Excel) which was kept in sealed opaque envelopes before
the start of the study (prepared by FX).
No premedication was administered. On arrival in oper-
ating theatre, all patients were preloaded with 10 mL · kg−1
of 37 °C Lactate Ringer’s solution at the speed of 10 ml ·
kg−1 · h−1 with an 18-G intravenous cannula through an
arm vein before anesthesia. Standard monitoring including
non-invasive blood pressure (NIBP), heart rate (HR), oxy-
gen saturation (SpO2) and electrocardiogram (ECG) were
applied and recorded.
Combined spinal-epidural (CSE) technique (using the
needle-through-needle technique) was performed in the
left lateral position for all the patients studied. In brief, epi-
dural puncture was performed with an 18-G Tuohy needle
at the estimated L2-3 interspace and the method of loss-of-
resistance-to-air technique (the air volume is not more
than 2 ml) was used to identify the epidural space. A 27-G
spinal needle with pencil tip was then passed via the Tuohy
needle to enter the subarachnoid space. One of two pre-
mixed study solutions was injected at a rate of 0.25 mL · S
−1through the spinal needle. After the injection, the spinal
needle was removed and an epidural catheter was then
inserted 3-4 cm into the epidural space. No drugs were
injected via the epidural catheter. The patient was then
turned to supine with a 15-degree tilt to the left side.
The mixed solutions for spinal anesthesia were prepared
before anesthesia by an anesthesia assistant (XZ), who did
not participate in the subsequent patient assessment, and
administered by a second attending anesthesiologist (FX
and WX) who remained blinded to the mixed solution
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contents. The mixed solution for patients in Control
group was: 0.5% bupivacaine + sufentanil 5 μg +0.5 mL
10% dextrose, diluted with 0.9% sodium chloride to a total
volume of 3 mL. The mixed solution for patients in Mag-
nesium group was: 0.5% bupivacaine + sufentanil 5 μg +
0.5 ml 10% dextrose + 0.1 ml 50% preservative-free mag-
nesium sulfate (50 mg) (WuXi Pharmaceutical Company,
China; Production batch: 1307201.) diluted with 0.9% so-
dium chloride to a total volume of 3 ml. An insulin syr-
inge (1 ml) was used to measure volumes less than 1 ml.
The dose of intrathecal bupivacaine administered to pa-
tients varied according to the up-and-down allocation
method [15]. In each group, for the first patient, the dose
of intrathecal bupivacaine was 8 mg. For the next patient,
the dose of intrathecal bupivacine was determined by the
response (effective or ineffective) of the previous patient
to the mixed intrathecal solution for spinal anesthesia in
the same group. If the response of the previous patient
was effective, the dose of intrathecal bupivacaine for the
next patient was decreased by 1 mg in that group. Con-
versely, if the response of the patient was ineffective, the
dose of intrathecal bupivacaine for the next patient was
increased by 1 mg in that group. Effective anesthesia was
defined as a bilateral T5 or above sensory block level
achieved within 10 min of intrathecal drug administration
and no additional epidural anesthetic was required for in-
traoperative pain. Ineffective anesthesia was defined as a
bilateral T5 sensory block level was not achieved within
10 min of intrathecal drug administration, or an additional
epidural anesthetic was needed to deal with intraoperative
pain (VAS ≥ 3) despite a T5 sensory level being obtained.
Additional epidural anesthetic was 5 ml of 2% lidocaine,
repeated every 10 min if necessary.
Measurements
Automatic measurements of non-invasive arterial pressure
(NIBP) and heart rate (HR) were recorded from the begin-
ning of spinal anesthesia at 2-min intervals for 10 min, and
then at 5-min intervals until the end of the surgery. An
average of three consecutive measurements at the time
when patient arrived in operating theatre with a supine
position was defined as basal NIBP and basal HR.
Hypotension was defined as a systolic arterial pressure
below 90 mmHg, or a decrease of more than 20% of basal
systolic blood pressure. Hypotension was treated with a
boluse of 40 μg intravenous phenylephrine, repeatedly if
needed. Bradycardia, defined as heart rate less than 55 beats
per min, was treated with 0.5 mg of atropine intravenously.
Sensory level was assessed bilaterally along the mid cla-
vicular line using a 17-G needle (patient was asked to re-
port pain sensation, if the block was not even bilaterally,
the lower side was chosen). The onset time of sensory block
was defined as the time between intrathecal injection and a
T10 sensory block level being achieved. The duration of
sensory block was defined as the time between the onset
time of sensory block and the recovery of sensory level of
T10. Motor block in the lower limbs was graded by a Brom-
age Score [16] (0 = able to lift extended leg; 1 = able to flex
knee but not lift extended leg; 2 = able to move foot only;
and 3 = unable to move foot). The onset time of motor
block was defined as the time between intrathecal injection
and a Bromage Score of 1 being reached. The duration of
motor block was defined as the period between the time of
motor block onset and a Bromage Score of 0. The duration
of spinal anesthesia [17] was defined as the period from
spinal injection to the first requirement of bolus of fentanyl
10 μg postoperatively with patient-controlled analgesia
(PCA) pump, which was set with a bolus of 10 μg fentanyl
and 10 min of locking time and without a background dose.
And patient did not received any other analgesics after
surgery Both the sensory and motor block characteristics
were noted every 1 min for the first 10 min after spinal
anesthesia, followed thereafter by 10-min intervals until the
end of the surgery and then by 30-min intervals after sur-
gery before the patient full recovery.
Subjective pain was assessed with a visual analogue
scale (VAS) ranged from 0 to 10 (0 = no pain, 10 =max-
imum undersirable pain) at the following timepoints:
skin incision, fetal delivery, peritoneal closure, skin clos-
ure, and 1, 4, 8, 12, 24 h postoperatively. At the end of
the surgery, patients were asked to grade the level of sat-
isfaction during surgery (1 = excellent; 2 = good; 3 = bad).
Side effects and complications of spinal anesthesia in-
cluding pruritus, shivering, severe sedation, nausea and
vomiting, post dural puncture headache (PDPH) and re-
spiratory depression (defined as breath rate < 12 bpm or
SpO2 < 90%) during surgery and the first 24 h postopera-
tively were also recorded by a fixed anesthesia assistant.
Sedation was ranked as none = awake and alert, mild =
awake but drowsy, moderate = asleep but arousable, se-
vere = not arousable. Any symptoms and signs of neuro-
logical deficit were also recorded. Umbilical arterial blood
was drawn for blood gas analysis immediately after deliv-
ery. The neonatal Apgar score was assessed at 1 min and
5 min after delivery by a pediatrician who was not in-
volved in this study.
Statistical analysis
The Dixon and Massey formula [15, 18] was applied to
calculate the ED50 for both groups. Sample size estima-
tion was calculated using the G*Power software. The pri-
mary outcome of the present study which is ED50 of
intrathecal bupivacaine for cesarean delivery. An esti-
mated ‘average’ SD of difference of the ED50 of intra-
thecal bupivacaine between groups is 0.5 mg, and power
was given at 0.95 to detect a difference of 1.6 SD
(0.8 mg) at P < 0.05. A minimum of 12 subjects was then
necessary in each of the two groups. Because the Dixon
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and Massey technique requires the sample size to be ap-
proximately twice this number (as the estimations of
ED50, SE and confidence interval (CI) 95% are based on
the number and distribution of the lesser occurring out-
come, which will be approximately 50% of the observa-
tions), therefore, 30 subjects were enrolled finally in
each of the two groups, allowing for possible drop-outs
and a potential deviation of the initial dose from the
center of the effective dose distribution.
Demographic data were collected and are presented as
count or mean ± SD as appropriate. Nominal data were
analyzed using the Chi-square test, normally distributed
continuous data were analyzed using Student’s t test and
non-normallly distributed continuous data (such as epi-
dural supplementations which were presented as median)
were analyzed using non-parametric Wilcoxon rank sum
test. Normal distribution was determined using the Kol-
mogorov–Smirnov test. Duration of spinal anesthesia was
also analyzed using Kaplan-Meier survival analysis. Statis-
tical analysis was performed with Graphpad Prism 5 (Ver-
sion 5.01). Statistical significance was defined as P < 0.05
(two-sided).
Results
The CONSORT diagram of the present study is showed
in Fig. 1. A total of 66 patients were assessed for eligibil-
ity, among them 60 patients were enrolled and randomly
assigned into the Control group (n = 30) or the Magne-
sium group (n = 30). All 60 patients finished the study
and were included into the final analysis.
There were no significant differences in the demo-
graphic and obstetric characteristics between the Con-
trol group and the Magnesium group (Table 1).
The ED50 of intrathecal hyperbaric bupivacaine for
cesarean delivery, determined using Dixon and Massay up-
down sequential method [19, 20], was 4.7 mg (95% CI, 4.4–
5.0 mg) in the Control group, and 4.9 mg (95% CI, 4.6–
5.2 mg) in the Magnesium group. There was no significant
difference in the ED50 of bupivacaine between the Magne-
sium group and the Control group (P = 0.53). The individ-
ual responses (effective or ineffective anesthesia) to the
corresponding intrathecal hyperbaric bupivacaine dose are
showed in Fig. 2. Thirteen patients in each group required
additional epidural 2% lidocaine to complement intra-
operative analgesia,and the mean total dose of additional
epidural 2% lidocaine was similar in the two groups [5 ml
(5–10 ml) vs. 5 ml (5–10 ml)].
Characteristics and efficacy of spinal anesthesia in pa-
tients with “effective anesthesia” are presented in Table 2.
The onset and duration of sensory and motor blockade
were longer in the Magnesium group than in the Con-
trol group (P < 0.001). Moreover, the duration of spinal
anesthesia was also significantly longer in the Magne-
sium group than in the Control group (183 ± 11 min vs
148 ± 9 min, P < 0.001) (Fig.3). The consumption of fen-
tanyl during the first 24 hours postoperatively were sig-
nificantly less in the Magnesium group than in Control
group (343 ± 42 μg vs 550 ± 49 μg, P < 0.001). The Mag-
nesium group has higher rate of excellent satisfaction
during intraoperative period than that in the Control
group (94.1% vs 52.9%, P = 0.017).
The incidence of side effects of spinal anesthesia, such as
hypotension, nausea and vomiting, shivering, pruritus, post
dural puncture headache (PDPH), severe sedation and re-
spiratory depression during perioperative period, were simi-
lar between groups (Table 3). Neonatal Apgar score at
5 min after delivery and umbilical arterial pH immediately
after delivery were also comparable between groups
(Table 3). No neurological deficit was observed in any pa-
tient in both groups during the first postoperative week.
Fig. 1 CONSORT diagram
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Discussion
We demonstrated that intrathecal magnesium sulfate
(50 mg) did not reduce the median effective dose (ED50)
of intrathecal bupivacaine, for cesarean delivery under
spinal anesthesia with bupivacaine coadministered with
5 μg sufentanil in healthy parturients.
Several previous studies [13, 19, 21, 22] reported that
the duration of spinal anesthesia was significantly pro-
longed by intrathecal magnesium sulfate, which is con-
sistent with the findings in the present study. The
present study also showed that adding magnesium sul-
fate intrathecally could significantly prolong the duration
of spinal anesthesia with bupivacaine and sufentanil
(184 min vs 148 min, P < 0.001). Evidence is conflicting
regarding the usage of intrathecal magnesium sulfate in
obstetric patients for prolonging the duration of spinal
anesthesia [13, 17, 22, 23], the study designs with or
without opioids may contribute to this discrepancy. This
synergistic effect has been already demonstrated in a rat
model by Kroin and colleagues [12] who found that the
addition of intrathecal magnesium increased the peak ef-
fect and area under the analgesic curve of intrathecal
morphine. The potentiation of opioid antinociception by
magnesium sulfate may last in the postoperative period,
explaining the decrease in consumption of postoperative
fentanyl found in the present study.
NMDA-receptor antagonists can diminish the activation
of C-fibers which leads to neuronal excitation, prevent
central sensitization elicited by peripheral nociceptive
stimulation [20, 24]. Magnesium sulfate, a noncompetitive
NMDA-receptor antagonist, has both independent and
synergistic analgesic properties. Kroin et al. demonstrated
in an animal study that intrathecal magnesium sulfate po-
tentiated the antinociceptive effect of morphine to nox-
ious thermal and mechanical stimulation at an incisional
pain site at the level of the spinal cord in a dose-
dependent fashion [12]. Mercieri et al. found that systemic
magnesium sulfate infusion (i.e. intravenous route), even
with large doses, did not increase cerebrospinal fluid
(CSF) magnesium concentrations, suggesting magnesium
sulfate exhibits insufficient blood-brain barrier penetration
[25, 26]. Hence, intrathecal route would be better for mag-
nesium sulfate administration to potentiate spinal
anesthesia than systemic route by which effective CSF
concentrations of magnesium required large doses that
may result in severe side effects.
Because intrathecal magnesium alone has been showed
to produce sensory and motor block, [27, 28] it might be
expected that magnesium potentiates the spinal block via
a synergistic interaction between NMDA antagonists and
local anesthetics, resulting in a reduction in the dose of
local anesthetics required for achieving effective spinal
anesthesia for certain surgical procedures. Unexpectedly,
the present study demonstrated that the ED50 of intra-
thecal bupivacaine for cesarean delivery in the Magnesium
group was not reduced when compared with the Control
group, suggesting that intrathecal 50 mg magnesium sul-
fate exhibits little or no effect on efficacy of spinal
anesthesia with local anesthetics for cesarean delivery. In
contrast to the lack of effect of magnesium on the median
effective dose of intrathecal bupivacaine in the current
study, previous studies suggested that intrathecal fentanyl
or sufentanil significantly reduce the dose (ED50 or ED95)
of spinal local anesthetics for cesarean delivery [3, 29, 30].
The possible underlying mechanism is that magnesium
may be removed from extracellular fluid more rapidly
than opioids, or that it may be specific to the NMDA






Age (y) 25 ± 3 26 ± 3 0.41
Height (cm) 162 ± 3 162 ± 3 0.42
Weight (kg) 72 ± 4 72 ± 4 0.84
Gestational age (week) 39 ± 1 39 ± 1 0.60
Duration of surgery (min) 45 ± 7 47 ± 7 0.41
Data are presented as mean ± SD. *Student t test
Fig. 2 Individual response to intrathecal hyperbaric bupivacaine at corresponding dose. Unfilled square (□) represents an ineffective response to
the corresponding dose of intrathecal bupivacaine for spinal anesthesia. Filled square (■) represents an effective response to the corresponding
dose of intrathecal bupivacaine for spinal anesthesia. Solid line represents the ED50 (dashed lines represent the 95% confidence interval, CI) of
intrathecal hyperbaric bupivacaine for caesarean delivery
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receptor channel and therefore has no influence on the
channels the local anesthetics act and opioid receptor sites
[14, 17]. Moreover, intrathecal magnesium sulfate exerts
its spinal action in a localized manner, [17] whereas,
fentanyl or sufentanil bind strongly to opioid receptors in
the dorsal horn of spinal cord, and may also exert a
supraspinal action by intrathecal cephalad spread, [31]
hence both fentanyl and sufentanil exhibit a significant
synergistic effect on local anesthetics. In addition, the dos-
age of intrathecal magnesium sulfate should be taken into
account. The dose of magnesium sulfate of 50 mg we
choose in the current study was based on majority of the
studies [13, 14, 17, 32] on clinical investigation of intrathecal
magnesium sulfate for cesarean delivery publically published
so far. However, whether higher dose of intrathecal
magnesium sulfate could reduce the dose (ED50 or ED95) of
intrathecal local anesthetics for cesarean delivery remains
unknown. Hence, it is warrant to conduct further studies
on optimal dose of magnesium sulfate for cesarean delivery.
The onset of sensory and motor blockade in the Magne-
sium group in the present study were found to be signifi-
cantly delayed when compared with the Control group,
which was in agreement with the findings of previous
studies [13, 21]. The clinical significance of this delay is
questionable because the delayed time was only about
1 min for both sensory and motor blockade onset in the
present study. It is difficult to explain this phenomenon
on mechanism of magnesium action upon central nervous
system. The effect of adding magnesium sulfate on the pH
and baricity of the spinal solution might be considered as
a possibility for this delay [22, 33]. Pascual-Ramirez sug-
gested that the onset delay when magnesium was added
could also indicate there is a modulation of the neuronal
electrical conduction blockade [34].
Concerns about the safety of intrathecal administration
of magnesium sulfate have been being considered. Preclin-
ical studies showed the impact of intrathecal magnesium
sulfate on neurological structure and functions appears
inconsistent among species [33]. In rats, intrathecal magne-
sium sulfate resulted in transient motor and sensory block
with no obvious adverse clinical and histological
consequences. In canines, intrathecal magnesium sulfate of
45–60 mg produced no neurological deficit and histopatho-
logical change in spinal cord [35]. In clinical studies,
intrathecal magnesium sulfate 50 mg was found to be safe
and effective, [13, 14, 17, 21, 22] which are similar to the
findings of the present study, in which we also did not find
any obvious symptoms and signs of dysfunction in nervous
system, reinforcing the safety of maternal intrathecal mag-
nesium. However, safety of intrathecal magnesium sulfate
would be argued because our study is a small study and no
specific assessments to assess safety were done. Hence, the
Table 2 Characteristics and efficacy of spinal anesthesia in








Sensory block (to pinprick)
Onset time to T10 (min) 4 ± 0 3 ± 0 <0.001*
Duration (min) 140 ± 9 121 ± 9 <0.001*
Motor block
Onset time (min) 4 ± 0 2 ± 0 <0.001*
Duration (min) 148 ± 12 125 ± 10 <0.001*
Duration of anesthesia (min) 183 ± 11 148 ± 9 <0.001*
Consumption of fentanyl
(μg)
343 ± 42 550 ± 49 <0.001*
Patient Satisfaction
Excellent [number (%)] 16 (94.1) 9 (52.9) 0.017#
Good [number (%)] 1 (5.9) 8 (47.1) 0.017#
Data are presented as mean± SD or number (%). *Student t test, #Chi-square test
Fig. 3 Duration of spinal anesthesia. Cumulative percentages of
patient remaining no pain after spinal injection in patients with
“effective anesthesia” in the Magnesium group (solid line, red area)
and in the Control group (dotted line, blue area), obtained using the
Kaplan–Meier survival analysis. Log-rank differences between the
two groups were significant (P < 0.001)
Table 3 Side effects of anesthesia and neonatal Apgar score






Hypotension 6(20.0) 8(26.7) 0.76#
Nausea and vomiting 12(40.0) 9(30.0) 0.59#
Shivering 5 (16.7) 6 (20.0) 1.00#
Pruritus 8(26.7) 7(23.3) 1.00#
PDPH 0 (0%) 1 (3.3) 1.00#
Severe sedation 0 0
Respiratory depression 0 0
Apgar score 10.0 ± 0.0 10.0 ± 0.0 1.00*
Umbilical artery pH 7.37 ± 0.04 7.38 ± 0.06 0.22*
Data are presented as number (percent) or mean ± SD. PPDH = post dural
puncture headache. *Student t test, #Chi-square test
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safety of intrathecal magnesium sulfate with larger sample
size and specific assessment variables, or with large dose
should be carefully evaluated in both animals and humans,
especially in pregnant populations.
Conclusions
In conclusion, in patients undergoing cesarean delivery
with spinal anesthesia, the addition of intrathecal mag-
nesium sulfate (50 mg) to spinal hyperbaric bupivacaine
combined with sufentanil did not reduce the ED50 of
intrathecal bupivacaine as determined with an up-down
sequential method, but prolonged the duration of spinal
anesthesia, reduced the consumption of post-operative
fentanyl, delayed the onset of both sensory and motor
blockade of spinal anesthesia. No obvious additional side
effects were found.
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